$24.82
-1.33-5.09%
À la clôture: Nov 16, 4:00 PM EST
$24.39
-0.43-1.73%
Après les heures: 5:19 PM EST

The average analyst price target for Rapport Therapeutics is $56.71, 132.5% above the current price. Of 14 analysts, 14 rate it Buy. Targets range from $28 to $89. The latest change came on Nov 5, 2026, when UBS lowered its price target on Rapport Therapeutics from $71 to $64 and kept a Buy rating.
Price Target Range — 9 Quarters
Analyst Consensus — 14 Analysts
Rating Trend — Last 9 Months